1. No category

3rd of March 2015
ROOM
PANORAMA A+C
08.00
Registration & Coffee
08.20
Welcome Speech
08.30
Public Markets and M&A Panel
Chaired by:
Stephanie Léouzon, Principal and Head of Torreya Partners Europe, Torreya Partners (Europe) LLC
Featuring:
Chandra Leo, Partner, HBM Partners AB
Jim Phillips, Chief Executive Officer, Midatech Group
Mick Cooper, Head of Research, Healthcare, Edison Group
Ravi Sodha, Senior Director Business Development, Actelion Pharmaceuticals
09.15
Investment Panel
Chaired by:
Tim Haines, Partner, Abingworth LLP
Featuring:
Arthur Franken, Partner, Gilde Healthcare
Bethan Hughes, Senior Business Analyst, Wellcome Trust
Graziano Seghezzi, Partner, Sofinnova Partners
Jeanne Bolger, Vice President Venture Investments, Johnson & Johnson Innovation
Lionel Carnot, Managing Director, Bay City Capital LLC
Margarita Chavez, Director, Ventures & Early Stage Collaborations, AbbVie
Markus Goebel, Partner, Novartis Venture Fund
Olivier Litzka, Partner, Edmond de Rothschild Investment Partners
10.15
Coffee Break
ROOM
PANORAMA A
10.30
Oncology I - Deal Making
Co-chaired by:
Tim Herpin, VP, Head of Transactions (UK), BD, AstraZeneca
Featuring:
Anne Altmeyer, Vice President, BD, Head of Negotiations, Oncology, Novartis
Pharmaceuticals
Frans Wuite, President & Chief Executive Officer, Oncos Therapeutics
Guillaume Vignon, Director BD Oncology – Global BD and Licensing, EMD Serono
Hamza Suria, President & CEO, AnaptysBio, Inc.
Mike Khan, CMO, Silence Therapeutics PLC
Stephen Sands, Commercial Lead, Oncology/Immunology, F. Hoffmann La Roche AG
10.30
11.15
PANORAMA C
Autoimmune & Inflammatory
Co-chaired by:
Chris Maggos, Consultant, BioConfidant Sàrl
Regina Hodits, General Partner, Wellington Partners
Featuring:
Adrian Mills, CBO, Novimmune SA
Andre Hoekema, SVP Corporate Development, Galapagos NV
Dinesh Patel, President & CEO, Protagonist Therapeutics, Inc.
Kia Motesharei, Head, Immunology Licensing, EMD Serono, Inc.
Lothar Steidler, Vice President Technology, ActoGeniX NV
Simon Kerry, CEO, Karus Therapeutics Ltd.
Rare & Orphan Diseases Panel
BERNE
EMERGING COMPANY
PRESENTATIONS
10.30
Amphera B.V.
10.40
Athera Biotechnologies AB
10.50
Saphetor SA
11.00
Calypso Biotech SA
11.10
Cell Therapy Ltd.
Rare & Orphan Diseases Panel
11.30
12.15
Oncology II - Investment
Co-chaired by:
Francois Thomas, Managing Director, Thomas Conseil SPRL
Featuring:
Anja König, Managing Director, Novartis Venture Fund
Bernhard Sixt, President & CEO, ImmunID
Carles Domenech, CEO, Ability Pharmaceuticals
Jakob Lindberg, CEO, Oncopeptides AB
Michael Scherz, Founder and Chief Executive Officer, Metys Pharmaceuticals
Peter Culpepper, CFO & COO, Provectus Biopharmaceuticals, Inc.
Thilo Schroeder, Partner, Nextech Invest Ltd.
Platform Technologies & Novel Therapeutics Panel
Co-chaired by:
Esteban Pombo-Villar, COO, Oxford BioTherapeutics
Katya Smirnyagina, Partner, Capricorn Venture Partners NV
Featuring:
Ajan Reginald, Chief Executive Officer, Cell Therapy Ltd.
Heinz Schwer, CEO, Lanthio Pharma
Fabian Buller, Director, New Ventures, Covagen AG / J&J Innovation
Malcolm Weir, Co-Founder, and CEO, Heptares Therapeutics
Rao Movva, Executive Director, Novartis Institutes for BioMedical Research, Inc.
13.00
Networking Lunch
ROOM
PANORAMA A
11.15
12.00
Co-chaired by:
David Phillips, Partner, S.R.One, Limited
Stjohn Mcgrath, Vice President BD, Bristol-Myers Squibb
Featuring:
Gary Clements, Head of Research Alliances, Shire Pharmaceuticals
Sten Verland, Partner, Sunstone Capital A/S
Neuroscience Panel
Chaired by:
Charles Bailey, Head of Search & Evaluation, Neurosciences,
Novartis Pharma AG
Chris Maggos, Consultant, BioConfidant Sàrl
Featuring:
Alexander Breidenbach, Director, Global Business Development, F.
Hoffmann La Roche AG
Graham Birrell, Regional Head, Business Development, OCT
Jesse Schulman, CEO, Canbex Therapeutics Limited
Kevin Cox, CEO, Imanova Ltd.
Konrad Glund, CEO, Probiodrug AG
Patrick Doyle, CEO, KineMed, Inc.
Seth Lederman, CEO, Tonix Pharmaceuticals Holding Corp.
PANORAMA C
EMERGING COMPANY
PRESENTATIONS
(continued)
11.20
Mendor
11.30
Oncos Therapeutics Ltd.
11.40
ISA Pharmaceuticals
11.50
Otic Pharma
12.00
Serendex Pharmaceuticals
A/S
12.10
Synthena AG
12.20
Histide AG
12.30
VTU Technology GmbH
12.40
Biophytis
12.50
Exploris Health AG
BERNE
Presenting Company TRACK A
Presenting Company TRACK B
Presenting Company TRACK C
14.00
Silence Therapeutics PLC
Lanthio Pharma
KineMed, Inc.
14.15
Helsinn Healthcare SA
Heptares Therapeutics
Probiodrug AG
14.30
AnaptysBio, Inc.
ImmunID
Tonix Pharmaceuticals Holding Corp.
14.45
Addex Therapeutics Ltd.
NovImmune SA
Kuros Biosurgery AG
15.00
???Oryx GmbH & Co
Glide Technologies
Hansa Medical AB
15.15
Midatech Pharma PLC
TBC - Arch Therapeutics
Provectus Biopharmaceuticals, Inc.
15.30
TBA
Karus Therapeutics Ltd.
TBA
15.45
TBA
Mirna Therapeutics, Inc.
TBA
16.00
Coffee Break
16.15
Early Stage Investment Panel
Chaired by:
Jasper Bos, Director, MS Ventures
Featuring:
Carina Schmidt, Chief Executive Officer, Athera Biotechnologies AB
Florian Kemmerich, Chief Executive Officer, Histide
Hans Schambye, Chief Executive Officer, GALECTO BIOTECH
Frank Kalkbrenner, Head Boehringer Ingelheim Venture Fund, Boehringer Ingelheim GmbH
Jesús Martin-Garcia, General Partner, Eclosion
Michèle Ollier, Partner, Index Ventures
Nanna Lüneborg, Investment Director, Novo Seeds, Novo A/S
Siro Perez, Venture Partner, Hadean Ventures
18.00
Networking Reception
20.00
End of Day 1
Presenting Company TRACK D
Presenting Company TRACK E
16.15
Oncopeptides AB
BerGenBio AS
16.30
Metys Pharmaceuticals AG
Mission Therapeutics Ltd.
16.45
Azanta A/S
Protagonist Therapeutics, Inc.
17.00
OCT
TBA
17.15
Ability Pharmaceuticals
Immunomic Therapeutics, Inc.
17.30
TBA
DanDrit Biotech
17.45
TBA
TBA
4th of March 2015
08.00
Registration & Coffee
08.30
Partnering Panel I
Co-chaired by:
Wilder Fulford, Principal, Torreya Partners (Europe) LLC
Featuring:
Corinne Savill, Head Business Development & Licensing, Novartis Pharma AG
Jane Atkins, Global Licensing & Business Development, Takeda Pharmaceuticals International GmbH
Philippe Lopes-Fernandes, SVP, Head of Global Licensing & Business Development, EMD Serono, Inc.
Stewart Kay, Director, Transactions, GlaxoSmithKline
09.15
Partnering Panel II
Co-chaired by:
Fintan Walton, CEO, PharmaVentures Ltd.
Featuring:
Serge Sagodira, Associate-Director, Head of Licensing, Business Development and Licensing, Debiopharm International S.A.
Luca Bolliger, Vice President and Group Licensing Director, RECORDATI S.A.
Jason Coloma, Global Head Venture & Innovation at Roche Partnering, F. Hoffmann La Roche AG
Pascal Touchon, Director - Scientific Cooperation & Business Development, Les Laboratoires Servier
Stjohn Mcgrath, Vice President Business Development, Bristol-Myers Squibb
Vincent de Groot, Sr. Director, Ventures & Early Stage Collaborations, AbbVie
10.00
Coffee Break
10.15
Vaccines Panel
Chaired by:
Chris Britten, Head, Business Development, Sanofi Pasteur MSD
Featuring:
Ted Fjällman, CEO, Prokarium Ltd.
William Hearl, President & Chief Executive Officer, Immunomic Therapeutics, Inc.
Wouter Latour, Chief Executive Officer, Vaxart, Inc.
11.00
MedTech & Diagnostics Panel
Co-chaired by:
Arthur Franken, Partner, Gilde Healthcare
Rainer Metzger, VP Global Business Development Pharma, Qiagen
Featuring:
Beat Merz, Managing Director, Rockport Venture Partners
Eduardo Margallo, CEO, MedLumics S.L.
Håkon Sæterøy, CEO, Pre Diagnostics AS
John Kelly, Founder & Chief Executive Officer, Atomo Diagnostics
Neil Butler, Chief Executive Officer, Spectromics
Thomas Taapken, Chief Executive Officer & Chief Financial Officer, Epigenomics AG
EMERGING COMPANY PRESENTATIONS
09.15
Prokarium Ltd.
09.25
Pre Diagnostics AS
09.35
MedLumics S.L.
09.45
Zytoprotec GmbH
09.55
TBA
Presenting Company TRACK F
10.15
Epigenomics AG
10.30
Cellular Biomedicine Group, Inc.
10.45
GamaMabs Pharma
11.00
BioCrypton, Inc.
11.15
Oryx GmbH & Co. KG – Oryx Translational
Medicine
11.30
11.45
EMERGING COMPANY PRESENTATIONS
10.15
Atomo Diagnostics
10.25
4D Lifetec AG
10.35
Galecto Biotech
10.45
TBA
10.55
TBA
11.05
TBA
11.15
TBA
11.25
TBA
TBA
Vaxart, Inc.
12.00
Bloomberg News Interview by Simeon Bennett
Boris Zaïtra, Head of Corporate M&A, F. Hoffmann-La Roche Ltd
12.30
Networking Lunch
13.30
Workshop: "Licensing Agreements: What was written was what was really meant?"
16.00
End of the Forum